权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Metabolic Regulation in Leukemia-Initatiating Cells

白血病起始细胞的代谢调节

基本信息

批准号：
9017971
负责人：
Daisuke Nakada
金额：
$ 46.22万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9017971
关键词：
Acute Myelocytic Leukemia Adipose tissue Affect Anorexia Antioxidants Attenuated CRISPR/Cas technology Cachexia Cancer Intervention Cancer Patient Carbon Cell physiology Cells Clinical Complex Dependence Development Diet Enzymes Glucose Glucose Transporter Goals Health Hematopoiesis Hematopoietic Hematopoietic stem cells Homeostasis In Vitro Intervention Lead Leukemic Cell MLL-AF9 Malignant Neoplasms Malnutrition Metabolic Metabolic stress Molecular Monitor Mus Nature Normal Cell Organ Oxidative Stress Pathway interactions Patients Physiological Reactive Oxygen Species Reducing Agents Regimen Regulation Reporting Resistance Role Skeletal Muscle Starvation Stress Syndrome System Testing Therapeutic biological adaptation to stress cancer cachexia cancer cell deprivation dietary control dietary manipulation dietary restriction glucose metabolism glucose uptake improved in vivo in vivo Model inhibitor/antagonist killings leukemia leukemogenesis mortality novel research study small molecule inhibitor targeted treatment upstream kinase wasting

项目摘要

DESCRIPTION (provided by applicant): Cancer cachexia is a complex multi-organ syndrome associated with anorexia and severe wasting of adipose tissue and skeletal muscle, contributing to the mortality of many patients. Even under this metabolic mayhem, cancer cells are somewhat protected from starvation and continue to expand. This raises a fundamental question of how cancer cells are protected from metabolic stress during cachexia. Understanding this cancer protective mechanism may lead to novel intervention to kill cancer cells under cachectic conditions, thereby improving patients' health. Particularly, development of cancer interventions rendering cancer cells sensitive to malnutrition observed in cachectic patients should be a valuable therapeutic option. We have evidence to suggest that AMPK, which senses energy stress and promotes metabolic homeostasis, may constitute this cancer protective mechanism. In preliminary results, we found that AMPK deletion from MLL-AF9 induced acute myelogenous leukemia (AML) significantly delayed the onset of AML, depleted leukemia-initiating cells (LICs), and disrupted metabolic homeostasis of AML cells. In contrast, deleting AMPK did not affect normal hematopoiesis, demonstrating that leukemic cells are more dependent on AMPK than normal hematopoietic cells. We further found that AMPK-deficient AML LICs are particularly sensitive to glucose deprivation in vitro. Strikingly, the delayed onset of leukemogenesis by AMPK-deficient AML was further delayed by placing the recipient mice on dietary restriction (DR), indicating that physiological metabolic stress in vivo renders leukemia particularly dependent on AMPK. We thus hypothesized that AMPK is required for LICs to resist metabolic stress, and that combining AMPK inhibition with dietary manipulation will suppress AML by disabling the metabolic stress response of AML. Our long-term goal is to understand how leukemia-initiating cells utilize metabolic regulators to survive malnourished conditions often found in cancer patients. In aim 1, we will determine how AMPK promotes the metabolic homeostasis of AML cells, by performing metabolic flux analysis and quantifying various metabolites in AML cells. In aim 2, we will determine how AMPK inhibition and dietary manipulation synergize to suppress leukemogenesis. In aim 3, we will test our hypothesis that Glut1 is a critical regulator of leukemogenesis controlled by AMPK, by deleting and/or inhibiting Glut1. We will also delete other candidate metabolic enzymes that regulate glucose metabolism and examine their function in leukemogenesis and conferring metabolic stress resistance to AML cells. Upon completion of this proposal, we will have deep understanding of the role of AMPK pathway in maintaining leukemia-initiating cells under metabolic stress. Since AMPK is not required for normal hematopoiesis, AMPK inhibition combined with dietary control shown in our study may offer a novel anti-leukemia therapy that targets leukemia without impairing normal HSCs and hematopoiesis.